Tag: lead

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against CTO Realty Growth, Inc. (“CTO” or the “Company”) (NYSE: CTO) and certain officers.   The class action, filed in the United States District Court for the Middle District of Florida, and docketed under 25-cv-01516, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired CTO securities between February 18, 2021 and June 24, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

Washington, DC, Aug. 08, 2025 (GLOBE NEWSWIRE) --

Link to ThinkCareBelieve's Article:  https://thinkcarebelieve.blog/2025/08/08/week-29-of-americas-shining-success/

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES
OR FOR DISSEMINATION IN THE UNITED STATES

Fitch Ratings has revised the Outlook on Iceland’s Long-Term-Foreign-Currency (LT FC) Issuer Default Rating (IDR) to Positive from Stable and affirmed the IDR at ‘A’.

Discover the Benefits of Titanium Cutting Boards for Hygiene, Durability, and Food Safety

Singapore, Singapore, Aug. 08, 2025 (GLOBE NEWSWIRE) -- The JinGangShan Asia-Pacific General Association today announced the official launch of two landmark initiatives valued at a combined SGD $43 billion, with strategic developments on Bintan Island, Indonesia, and Penang Island, Malaysia. These flagship projects—the ultra-secure Bintan Citadel and the bi-national Life Memorial Services Park—mark a significant milestone in the Association’s mission to create the world’s foremost sanctuary for safeguarding human cultural heritage and wealth for generations to come.

CAMBRIDGE, Mass., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.^® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to new employees. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employees entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).